Incanthera PLC's (AQSE:INC) CEO Simon Ward and Kevin Hammond talk to Proactive London's Katie Pilbeam about new positive data from new skin permeation and sensitisation studies of its Sol skin cancer technology.
Both Simon and Kevin explain that Sol is a cream designed to deliver an active agent into the skin that is known to prevent the formation of solar (actinic) keratosis and skin cancer.
The results reveal that Sol is 'non-irritant' and comparable to baby sun protection products tested previously. They discuss the route to commercialism and hint at 'exciting conversations' happening behind closed doors.